Biomerica Inc
$ 2.14
-0.47%
24 Apr - close price
- Market Cap 6,613,200 USD
- Current Price $ 2.14
- High / Low $ 2.18 / 2.11
- Stock P/E N/A
- Book Value 1.09
- EPS -1.61
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -0.94 %
- 52 Week High 4.60
- 52 Week Low 1.87
About
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology company specializing in the development and manufacturing of cutting-edge diagnostic solutions across the medical and food sectors. With a strong focus on proprietary testing methods for managing metabolic diseases, gastrointestinal disorders, and food intolerances, Biomerica is committed to improving healthcare outcomes. The company actively engages in strategic research collaborations, positioning itself to address critical unmet medical needs and harness growth opportunities in the rapidly evolving diagnostics landscape. Leveraging technological advancements and a patient-centered approach, Biomerica is well-positioned to lead transformational changes in global healthcare diagnostics.
Analyst Target Price
$13.00
Quarterly Earnings
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 | May 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-14 | 2026-01-14 | 2025-10-13 | 2025-08-29 | 2025-04-10 | 2025-01-14 | 2024-10-15 | 2024-08-28 | 2024-04-12 | 2024-01-16 | 2023-10-12 | 2023-08-25 |
| Reported EPS | -0.4358 | -0.45 | 0.0008 | -0.73 | -0.0606 | -0.0555 | -0.0782 | -0.0845 | -0.114 | -0.0896 | -0.1065 | -0.11 |
| Estimated EPS | None | 0 | None | 0 | None | None | None | None | None | 0.04 | -0.02 | -0.08 |
| Surprise | 0 | -0.45 | 0 | -0.73 | 0 | 0 | 0 | 0 | 0 | -0.1296 | -0.0865 | -0.03 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | -324% | -432.5% | -37.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BMRA
2026-04-17 03:08:37
Biomerica has announced that a Medicare Administrative Contractor (MAC) has confirmed individual claim review for its InFoods IBS diagnostic test. This confirmation opens a scalable pathway for commercialization within the Medicare system, allowing Biomerica to seek payment for its innovative blood test designed to identify foods that trigger Irritable Bowel Syndrome symptoms. The company anticipates a significant increase in Medicare-covered patients as a result, broadening access to InFoods IBS.
2026-04-16 17:39:49
Biomerica Inc. (BMRA) has secured Medicare coverage eligibility for its inFoods IBS test on a case-by-case basis through its CLIA-certified laboratory partner, Ethos Laboratories. This development, aligned with CMS policies, is expected to drive potential revenue growth by enhancing accessibility to Biomerica's diagnostic products for chronic diseases. Despite this positive news, the company faces challenges in profitability and growth, reflected in its GF Score™ of 58 and low profitability/growth ranks, suggesting moderate potential for investors.
2026-04-16 12:39:17
Biomerica (NASDAQ: BMRA) announced that its inFoods® IBS test is now eligible for individual claim review by Medicare Administrative Contractors (MACs), establishing a pathway for Medicare billing. The test has a dedicated CPT PLA code effective October 1, 2025, and a national payment rate of $300 for services on or after January 1, 2026. This development allows for near-term revenue generation for Biomerica, contingent on proper documentation and medical necessity for each claim.
2026-04-16 08:19:00
Biomerica, Inc. announced that the Medicare Administrative Contractor (MAC) has confirmed individual claim review for its inFoods IBS test, allowing for Medicare coverage on a claim-by-claim basis. This confirmation allows Biomerica's CLIA-certified laboratory partner, Ethos Laboratories, to begin generating revenue from inFoods IBS claim submissions for services provided on or after January 1, 2026. The inFoods IBS test has a dedicated CPT code, a $300 national payment rate established by CMS, and is supported by Level 1 clinical evidence, positioning it for successful claim adjudication.
2026-04-14 19:40:33
Biomerica, Inc. has launched its inFoods IBS platform in Canada through strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs. Phoenix Airmid Biomedical will handle exclusive distribution and sales across Canada, utilizing its existing healthcare relationships. CanAlt Health Labs will provide certified laboratory processing for the inFoods IBS tests, delivering results to medical professionals nationwide.
2026-04-14 12:40:33
Biomerica has launched its inFoods® IBS platform in Canada through strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs. This marks Biomerica's first commercial entry into the Canadian market, where an estimated 5 million people may suffer from IBS. The inFoods® IBS platform offers a personalized, non-pharmaceutical approach to managing gastrointestinal symptoms by identifying patient-specific food triggers.
